£1.6m market cap
2p last close
NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital heath (Wanda), diagnostics (Vortex, ProAxsis, Glycotest) and therapeutics (PDS Biotech).
Investment summary
NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. The company is focused on digital health, diagnostics and therapeutics with the portfolio consisting of four core investments in which it has controlling stakes (Vortex, Wanda, ProAxsis and Glycotest) and one material investment (PDS). Importantly, Glycotest announced that Fosun Pharma agreed to a $10m investment in Glycotest in exchange for a 40% interest in the company as well as the China rights for Glycotest’s hepatocellular carcinoma panel. PDS also recently agreed to merge with Nasdaq-listed Edge Therapeutics. NetScientific has initiated an exploration of strategic alternatives.
Y/E Dec |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 0.5 | (12.6) | (12.3) | (20.6) | N/A | N/A |
| 2017A | 0.4 | (10.8) | (9.5) | (13.6) | N/A | N/A |
| 2018E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019E | N/A | N/A | N/A | N/A | N/A | N/A |
| Last updated on 19/02/2019 | ||||||
Industry outlook
NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.
Last updated on 19/02/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (£m) | 0.3 |
| Forecast gearing ratio (%) | 4 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Sir Richard Sykes | Chairman |
| Dr François Martelet | CEO |
| Ian Postlethwaite | CFO |
